Confirmatory testing (i.e., MRI, repeat biopsy, or genomics within 6–12 months to rule out more aggressive disease) is a linchpin of active surveillance for low-risk prostate cancer. Yet, follow-through remains inconsistent–a trend not significantly altered by a Michigan payer-backed payment incentive that promised enhanced reimbursement if ≥45% of patients within a physician’s purview completed testing. | Arnav Srivastava, JAMA Netw Open 2025
